Business ❯ Pharmaceutical Industry

Market Dynamics

Pricing Strategies Drug Pricing Drug Pricing Strategies Drug Sales Generic Drugs Competition Drug Competition Supply Chain Cost Management Investment Trends Stock Performance Export Trends Drug Development Product Launch Investment Strategies Pricing Issues Generic Competition Patent Expiration Weight Loss Drugs Stock Market Partnerships Drug Demand Competitors Production Costs Investment Eli Lilly Digital Therapeutics Profitability Risks Pricing Pressure Regional Market Share Product Protection Strategies Weight Loss Drug Market Pricing Models Drug Costs Stock Market Impact Investor Reactions Pharmacy Benefit Managers Competitiveness Innovation China Vaccine Development Product Safety Export Strategies Import Regulations Sales Volumes Debt Issues Price Increases Sales Performance Sales Forecasting Supplier Relations Biosimilar Development Anti-Obesity Medications Tariffs Supply Chain Issues Export Challenges Revenue Generation Drug Approval Process Consumer Access Cancer Therapies Price Control Innovation Strategies U.S. Market Price Concessions Drug Approval Generic Drug Pricing Telehealth Services Generics Apothecary Economics Competition Laws Patents Monopolies Generic Medications Product Development Competition Levels Competition in Pharmaceuticals Price Negotiation Competitive Analysis Consumer Behavior Imports Regulatory Environment Weight Loss Medications Novo Nordisk

U.S. Drug Prices Fall at Fastest Pace in 63 Years, CMS Says

The administration says new price‑matching deals and an expanded TrumpRx platform are driving lower retail pharmacy prices

FDA Advisory Panel Narrowly Backs Compounding of Six Unapproved Peptides

Sanofi Confirms Intermittent U.S. Supply of Lantus SoloStar Pens

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

India Tightens Oversight of GLP-1 Drugs as Semaglutide Generics Proliferate

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

Analyses Find Limited Savings as TrumpRx Reaches 54 Drugs

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65

WHO Endorses Long-Term GLP-1 Use for Obesity as Indian Ruling Opens Production and Safety Alerts Expand

Sarepta Shares Plunge After ESSENCE Phase 3 Miss in Duchenne Trial

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

FDA Approves Weekly Leqembi Autoinjector for At-Home Maintenance in Early Alzheimer’s

FDA Flags Possible License Revocation for Sarepta’s Elevidys